Immunotherapy for advanced or recurrent hepatocellular carcinoma

doi:10.4251/wjgo.v15.i3.405

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 15, Issue 3

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (4343)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-5) series.

Item

Count

PDF

176

WORD

HTML

2277

Figures (1-2)

212

Tables (1-5)

254

Sum=2957

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

198

Download

584

Sum=782

Publishing Process of This Article

Item

Count

Browse

156

Download

448

Sum=604

Mar 15, 2023 (publication date) through Dec 24, 2024

Times Cited of This Article

Times Cited (2)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Gastrointest Oncol. Mar 15, 2023; 15(3): 405-424
Published online Mar 15, 2023. doi: 10.4251/wjgo.v15.i3.405

Open in New Tab Full Size Figure Download Figure

Figure 1 Current approaches of immunotherapy. CAR-Ts: Chimeric antigen receptor expressing T cells; CIKs: Cytokine-induced killer cells; DCs: Dendritic cells; HCC: Hepatocellular carcinoma; NKs: Natural killer cells; OVs: Oncolytic virus; TACE: Transcatheter arterial chemoembolization.

Open in New Tab Full Size Figure Download Figure

Figure 2 Immune targets and immune checkpoint inhibitors. CTLA-4: Cytotoxic T lymphocyte-associated antigen 4; ICI: Immune checkpoint inhibitor; LAG3: Lymphocyte-activation gene 3; PD-1: Programmed cell death protein 1; PD-L1: Programmed death ligand 1; TIM3: T cell immunoglobulin and mucin domain containing-3.

Citation: Luo YZ, Zhu H. Immunotherapy for advanced or recurrent hepatocellular carcinoma. World J Gastrointest Oncol 2023; 15(3): 405-424
URL: https://www.wjgnet.com/1948-5204/full/v15/i3/405.htm
DOI: https://dx.doi.org/10.4251/wjgo.v15.i3.405